Loading…
Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review
A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th E...
Saved in:
Published in: | Case reports in psychiatry 2017-01, Vol.2017 (2017), p.1-11 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593 |
---|---|
cites | cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593 |
container_end_page | 11 |
container_issue | 2017 |
container_start_page | 1 |
container_title | Case reports in psychiatry |
container_volume | 2017 |
creator | Bilbily, John de Leon, Jose McCollum, Betsy |
description | A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine. |
doi_str_mv | 10.1155/2017/2402731 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A551495615</galeid><doaj_id>oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295</doaj_id><sourcerecordid>A551495615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</originalsourceid><addsrcrecordid>eNqNkkFvEzEQhVcIRKvSG2dkiSOk9XjtXZsDUhSVUikSEi2CmzW7nk0cJevg3W0Ev75OE1IiccA-2Bp_8zRPfln2GvgFgFKXgkN5KSQXZQ7PslPBDR8VOtfPD3fx4yQ777oFT6tQkBfmZXYidG4KDeo0CxPssQ-tR3ZLdWgdxl-sD-x2cI5aNlmG37j2LbHvvp-7iBtcfmBjNsGO2CaV2N08ErGvtCbsybGrte-Co45h6xiyqe8pYj_ELXLvafMqe9HgsqPz_XmWfft0dTf5PJp-ub6ZjKejWkIBI9UIULlKxsg5AxxkQy43jS6FScYbl1cFoOCVaEoDWpGQkrQqlDSVrJTJz7Kbna4LuLDr6FfJmA3o7WMhxJnF2Pt6SVYrJWrNgZOUUqDDEpwRJMkoqoVRSevjTms9VCtyNbV9xOWR6PFL6-d2Fu6tyksutUgCb_cCMfwcqOvtIgyxTf4taA0geCnNEzXDNJVvm5DE6pXvajtWCqRRBWyHufgHlbajlU8fSI1P9aOG97uGOoaui9QcBgdutyGy2xDZfYgS_uZvswf4T2QS8G4HzH1Ky8b_pxwlhhp8oh_nk_kD-rbVPw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1881120749</pqid></control><display><type>article</type><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bilbily, John ; de Leon, Jose ; McCollum, Betsy</creator><contributor>Inada, Toshiya</contributor><creatorcontrib>Bilbily, John ; de Leon, Jose ; McCollum, Betsy ; Inada, Toshiya</creatorcontrib><description>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</description><identifier>ISSN: 2090-682X</identifier><identifier>EISSN: 2090-6838</identifier><identifier>DOI: 10.1155/2017/2402731</identifier><identifier>PMID: 28396815</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Anesthesia ; Case Report ; Causality ; Clozapine ; Colleges & universities ; GABA ; Hospitals ; Medical research ; Mental disorders ; Mental health ; Neurosciences ; Patients ; Psychosis ; Psychotropic drugs</subject><ispartof>Case reports in psychiatry, 2017-01, Vol.2017 (2017), p.1-11</ispartof><rights>Copyright © 2017 John Bilbily et al.</rights><rights>COPYRIGHT 2017 John Wiley & Sons, Inc.</rights><rights>Copyright © 2017 John Bilbily et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 John Bilbily et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</citedby><cites>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</cites><orcidid>0000-0002-7756-2314</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1881120749/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1881120749?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28396815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Inada, Toshiya</contributor><creatorcontrib>Bilbily, John</creatorcontrib><creatorcontrib>de Leon, Jose</creatorcontrib><creatorcontrib>McCollum, Betsy</creatorcontrib><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><title>Case reports in psychiatry</title><addtitle>Case Rep Psychiatry</addtitle><description>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</description><subject>Anesthesia</subject><subject>Case Report</subject><subject>Causality</subject><subject>Clozapine</subject><subject>Colleges & universities</subject><subject>GABA</subject><subject>Hospitals</subject><subject>Medical research</subject><subject>Mental disorders</subject><subject>Mental health</subject><subject>Neurosciences</subject><subject>Patients</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><issn>2090-682X</issn><issn>2090-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkkFvEzEQhVcIRKvSG2dkiSOk9XjtXZsDUhSVUikSEi2CmzW7nk0cJevg3W0Ev75OE1IiccA-2Bp_8zRPfln2GvgFgFKXgkN5KSQXZQ7PslPBDR8VOtfPD3fx4yQ777oFT6tQkBfmZXYidG4KDeo0CxPssQ-tR3ZLdWgdxl-sD-x2cI5aNlmG37j2LbHvvp-7iBtcfmBjNsGO2CaV2N08ErGvtCbsybGrte-Co45h6xiyqe8pYj_ELXLvafMqe9HgsqPz_XmWfft0dTf5PJp-ub6ZjKejWkIBI9UIULlKxsg5AxxkQy43jS6FScYbl1cFoOCVaEoDWpGQkrQqlDSVrJTJz7Kbna4LuLDr6FfJmA3o7WMhxJnF2Pt6SVYrJWrNgZOUUqDDEpwRJMkoqoVRSevjTms9VCtyNbV9xOWR6PFL6-d2Fu6tyksutUgCb_cCMfwcqOvtIgyxTf4taA0geCnNEzXDNJVvm5DE6pXvajtWCqRRBWyHufgHlbajlU8fSI1P9aOG97uGOoaui9QcBgdutyGy2xDZfYgS_uZvswf4T2QS8G4HzH1Ky8b_pxwlhhp8oh_nk_kD-rbVPw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Bilbily, John</creator><creator>de Leon, Jose</creator><creator>McCollum, Betsy</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>AHMDM</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7756-2314</orcidid></search><sort><creationdate>20170101</creationdate><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><author>Bilbily, John ; de Leon, Jose ; McCollum, Betsy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anesthesia</topic><topic>Case Report</topic><topic>Causality</topic><topic>Clozapine</topic><topic>Colleges & universities</topic><topic>GABA</topic><topic>Hospitals</topic><topic>Medical research</topic><topic>Mental disorders</topic><topic>Mental health</topic><topic>Neurosciences</topic><topic>Patients</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilbily, John</creatorcontrib><creatorcontrib>de Leon, Jose</creatorcontrib><creatorcontrib>McCollum, Betsy</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>قاعدة العلوم الإنسانية - e-Marefa Humanities</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case reports in psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilbily, John</au><au>de Leon, Jose</au><au>McCollum, Betsy</au><au>Inada, Toshiya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</atitle><jtitle>Case reports in psychiatry</jtitle><addtitle>Case Rep Psychiatry</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>2090-682X</issn><eissn>2090-6838</eissn><abstract>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28396815</pmid><doi>10.1155/2017/2402731</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7756-2314</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2090-682X |
ispartof | Case reports in psychiatry, 2017-01, Vol.2017 (2017), p.1-11 |
issn | 2090-682X 2090-6838 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295 |
source | Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central |
subjects | Anesthesia Case Report Causality Clozapine Colleges & universities GABA Hospitals Medical research Mental disorders Mental health Neurosciences Patients Psychosis Psychotropic drugs |
title | Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catatonia%20Secondary%20to%20Sudden%20Clozapine%20Withdrawal:%20A%20Case%20with%20Three%20Repeated%20Episodes%20and%20a%20Literature%20Review&rft.jtitle=Case%20reports%20in%20psychiatry&rft.au=Bilbily,%20John&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=2090-682X&rft.eissn=2090-6838&rft_id=info:doi/10.1155/2017/2402731&rft_dat=%3Cgale_doaj_%3EA551495615%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1881120749&rft_id=info:pmid/28396815&rft_galeid=A551495615&rfr_iscdi=true |